On July 24, 2026, a volunteer was injected with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola. This strain has been linked to a deadly outbreak in the Democratic Republic of Congo.
The trial, conducted by Oxford University, aims to assess the vaccine's effectiveness and safety in combating the virus that has caused significant health crises in the region.
More than 1,270 individuals have been affected by the outbreak, highlighting the urgent need for effective vaccination strategies to control the spread of Ebola.